Abstract
Recent advances in radiotherapy technology now enable us to deliver a booster dose of radiation to small target fractions in a malignant tumor. To fully exploit this technology in cancer therapy, it is necessary to clarify the location and dynamics of radioresistant cells in heterogeneous tumor microenvironments. Tumor cells in which the transcriptional activity of hypoxia-inducible factor 1 (HIF-1) is extremely high are recognized as potential targets, because HIF-1 has been strongly associated with tumor angiogenesis, invasion, metastasis, and poor prognosis after radiation therapy. In this review, we focus on recent advances in our understanding of [1] the molecular mechanism underlying the regulation of HIF-1s transcriptional activity, [2] the influence of radiation-induced alterations of the tumor microenvironment on intratumor HIF-1 activity, [3] HIF-1-mediated tumor radioresistance, and [4] an optimal treatment protocol for the combination of a HIF-1 inhibitor and radiation therapy.
Keywords: Radiation Therapy, tumor hypoxia, tumor microenvironment, hypoxia-inducible factor 1 (HIF-1), reoxygenation, radioresistance, ROS, reactive oxygen species
Current Signal Transduction Therapy
Title: Hypoxia-Inducible Factor 1 in Tumor Radioresistance
Volume: 5 Issue: 3
Author(s): Hiroshi Harada and Masahiro Hiraoka
Affiliation:
Keywords: Radiation Therapy, tumor hypoxia, tumor microenvironment, hypoxia-inducible factor 1 (HIF-1), reoxygenation, radioresistance, ROS, reactive oxygen species
Abstract: Recent advances in radiotherapy technology now enable us to deliver a booster dose of radiation to small target fractions in a malignant tumor. To fully exploit this technology in cancer therapy, it is necessary to clarify the location and dynamics of radioresistant cells in heterogeneous tumor microenvironments. Tumor cells in which the transcriptional activity of hypoxia-inducible factor 1 (HIF-1) is extremely high are recognized as potential targets, because HIF-1 has been strongly associated with tumor angiogenesis, invasion, metastasis, and poor prognosis after radiation therapy. In this review, we focus on recent advances in our understanding of [1] the molecular mechanism underlying the regulation of HIF-1s transcriptional activity, [2] the influence of radiation-induced alterations of the tumor microenvironment on intratumor HIF-1 activity, [3] HIF-1-mediated tumor radioresistance, and [4] an optimal treatment protocol for the combination of a HIF-1 inhibitor and radiation therapy.
Export Options
About this article
Cite this article as:
Harada Hiroshi and Hiraoka Masahiro, Hypoxia-Inducible Factor 1 in Tumor Radioresistance, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920229
DOI https://dx.doi.org/10.2174/157436210791920229 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of ABC Transporters by Nuclear Receptors: Physiological, Pathological and Pharmacological Aspects
Current Medicinal Chemistry Multimodality Imaging of RNA Interference
Current Medicinal Chemistry DNAzyme Delivery Approaches in Biological Settings
Current Medicinal Chemistry Anti-Proliferative, Anti-Inflammatory, Anti-Ulcerogenic and Wound Healing Properties of Chitosan
Current Bioactive Compounds Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design The Role of Nuclear Factor-κB in Inflammatory Lung Disease
Inflammation & Allergy - Drug Targets (Discontinued) N-Aryl-5-aminopyrazole: A Versatile Architecture in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases
Current Topics in Medicinal Chemistry The Advance of Dendrimers - A Versatile Targeting Platform for Gene/Drug Delivery
Current Pharmaceutical Design The Effects of Dietary Supplements that Overactivate the Nrf2/ARE System
Current Medicinal Chemistry “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Current Pharmaceutical Design Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand
Current Radiopharmaceuticals